Postoperative Use of Anti-TNF-α Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study
Approximately 80% of patients with Crohn's disease will require surgery. Surgery for Crohn's disease is not curative, and recurrence is typical. In this cohort study, based on nationwide Danish registries, we examined the association between postoperative treatment with anti-tumor necrosis factor α (anti-TNF-α) agents and reoperation. The association was examined in cohort 1 = patients not treated with anti-TNF-α agents within 6 months before operation, cohort 2 = patients treated with anti-TNF-α agents within 6 months before operation. Within both cohorts, we defined postoperative exposure to anti-TNF-α agents as at least 1 treatment within 6 months after the first operation and the reference cohorts were those not treated. Patients were followed from 6 months after operation and until 5 years. We used Cox proportional-hazards regression to compute adjusted hazard ratios with 95% confidence intervals. In cohort 1, 31 (1.3%) were treated with anti-TNF-α agents within 6 months after operation and compared with those not treated, the adjusted hazard ratio of reoperation among those treated with anti-TNF-α agents was 3.53 (95% confidence interval: 1.61-7.72). In cohort 2, 63 (16.3%) were treated with anti-TNF-α agents within 6 months after operation, and the corresponding adjusted hazard ratio of reoperation was 2.16 (95% confidence interval: 1.11-4.18). Our data suggest that anti-TNF-α treatment within 6 months after the first operation is not associated with a reduction in the need for subsequent operation. Uncontrolled confounding might have influenced our results, and, furthermore, future studies are warranted to clarify whether our study population is different from populations most often associated with postoperative anti-TNF-α treatment..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - 22(2016), 3, Seite 599 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kjeldsen, Jens [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1097/MIB.0000000000000647 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1973318660 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1973318660 | ||
| 003 | DE-627 | ||
| 005 | 20210716081339.0 | ||
| 007 | tu | ||
| 008 | 160427s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MIB.0000000000000647 |2 doi | |
| 028 | 5 | 2 | |a PQ20160430 |
| 035 | |a (DE-627)OLC1973318660 | ||
| 035 | |a (DE-599)GBVOLC1973318660 | ||
| 035 | |a (PRQ)c1049-8667e6561d51460f9815b8f41b4ac625f9ecaa312f6941046121d75edc8f25df3 | ||
| 035 | |a (KEY)0265145920160000022000300599postoperativeuseofantitnfagentsinpatientswithcrohn | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Kjeldsen, Jens |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postoperative Use of Anti-TNF-α Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Approximately 80% of patients with Crohn's disease will require surgery. Surgery for Crohn's disease is not curative, and recurrence is typical. In this cohort study, based on nationwide Danish registries, we examined the association between postoperative treatment with anti-tumor necrosis factor α (anti-TNF-α) agents and reoperation. The association was examined in cohort 1 = patients not treated with anti-TNF-α agents within 6 months before operation, cohort 2 = patients treated with anti-TNF-α agents within 6 months before operation. Within both cohorts, we defined postoperative exposure to anti-TNF-α agents as at least 1 treatment within 6 months after the first operation and the reference cohorts were those not treated. Patients were followed from 6 months after operation and until 5 years. We used Cox proportional-hazards regression to compute adjusted hazard ratios with 95% confidence intervals. In cohort 1, 31 (1.3%) were treated with anti-TNF-α agents within 6 months after operation and compared with those not treated, the adjusted hazard ratio of reoperation among those treated with anti-TNF-α agents was 3.53 (95% confidence interval: 1.61-7.72). In cohort 2, 63 (16.3%) were treated with anti-TNF-α agents within 6 months after operation, and the corresponding adjusted hazard ratio of reoperation was 2.16 (95% confidence interval: 1.11-4.18). Our data suggest that anti-TNF-α treatment within 6 months after the first operation is not associated with a reduction in the need for subsequent operation. Uncontrolled confounding might have influenced our results, and, furthermore, future studies are warranted to clarify whether our study population is different from populations most often associated with postoperative anti-TNF-α treatment. | ||
| 700 | 1 | |a Nielsen, Jan |4 oth | |
| 700 | 1 | |a Larsen, Michael Due |4 oth | |
| 700 | 1 | |a Qvist, Niels |4 oth | |
| 700 | 1 | |a Nørgård, Bente Mertz |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d Oxford : Oxford University Press, 1995 |g 22(2016), 3, Seite 599 |w (DE-627)216856914 |w (DE-600)1340971-2 |w (DE-576)090828844 |x 1078-0998 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2016 |g number:3 |g pages:599 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1097/MIB.0000000000000647 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26650149 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2016 |e 3 |h 599 | ||